In vivo and in vitro bioactivity of a "precursor of apatite" treatment on polyetheretherketone
In vivo and in vitro bioactivity of a "precursor of apatite" treatment on polyetheretherketone
复制标题
DOI：
10.1016/j.actbio.2019.04.041
复制
发表时间：
2019-06-01
影响因子：
9.7
通讯作者：
Matsuda, Shuichi
中科院分区：
文献类型：
--
作者：
Masamoto, Kazutaka;Fujibayashi, Shunsuke;Matsuda, Shuichi
我们最近开发了一种表面处理，即“磷灰石前体”（PrA），通过简单的低温工艺用于聚醚醚酮（PrA-PEEK），旨在实现更强、更快的骨粘附。处理包括三个步骤：H2SO 4浸泡，暴露于O-2等离子体放电，和碱性模拟体液（碱性SBF）处理。该方法在PEEK上产生均匀的无定形磷酸钙细颗粒，并且我们证实PrA-PEEK在SBF浸泡测试中具有优异的磷灰石形成能力。在本研究中，在兔胫骨中使用PEEK植入物，机械测试以及组织学和放射学分析表明，PrA在早期阶段（4周和8周）为PEEK基材提供了优异的骨结合性能和骨传导性，并延长至16周。使用MC 3 T3-E1细胞的体外研究通过XTT测定揭示，PEEK基底上的PrA没有导致细胞毒性，尽管PrA处理似乎抑制了7天孵育后整合素β-1和Alp的基因表达，如实时PCR所示。总的来说，PrA治疗成功地使PEEK基材具有体内骨结合特性，并且该治疗是一种安全且有前途的方法，可用于临床。体内和体外生物活性之间存在不一致性，这种差异表明磷灰石的形成并不总是需要成骨细胞在非常早期的活化，并且在细胞和生物体水平的最佳条件可能是不同的。为了进一步改善PEEK基材料的临床结果，我们在PEEK表面开发了“磷灰石前体”（PrA）处理，以赋予骨结合性能。这种处理的优点是不需要高温处理或特殊化学品，而且价格便宜。本研究阐明了优良的体内骨结合性能的PrA治疗。此外，结果揭示了重要的见解，表明最佳条件，特别是磷酸钙中的润湿性和结晶度，在细胞和生物体水平上不同。此外，我们的研究结果表明，体内生物活性的预测应结合多种体外试验进行。(C)2019 Acta Materialia Inc.由爱思唯尔有限公司出版。保留所有权利。
We recently developed a surface treatment, "precursor of apatite" (PrA), for polyetheretherketone (PrA-PEEK) via a simple, low-temperature process aiming to achieve stronger and faster adhesion to bone. The treatment involves three steps: H2SO4 immersion, exposure to O-2 plasma discharge, and alkaline simulated body fluid (alkaline SBF) treatment. This method produces homogeneous fine particles of amorphous calcium phosphate on the PEEK, and we confirmed that PrA-PEEK had excellent apatite formation ability in an SBF immersion test. In the present study using PEEK implants in rabbit tibia, mechanical tests, and histological and radiological analyses revealed that PrA provided the PEEK substrate with excellent bone-bonding properties and osteo-conductivity at early stages (4 and 8 weeks), extending to 16 weeks. In vitro study using MC3T3-E1 cells revealed via XTT assay that PrA on the PEEK substrate resulted in no cytotoxicity, though PrA treatment seemed to suppress gene expression of integrin beta-1 and Alp after 7-day incubation as shown by real-time PCR. On the whole, PrA treatment succeeded in giving in vivo bone-bonding properties to the PEEK substrate, and the treatment is a safe and promising method that can be applied in clinical settings. There was an inconsistency between in vivo and in vitro bioactivity, and this discrepancy indicated that apatite formation does not always need activation of osteoblasts at very early stage and that optimal conditions at cell and organism level may be different.Statement of SignificancePolyetheretherketone (PEEK) is an attractive engineering polymer used for spine and dental surgery. To further improve clinical outcome of PEEK-based materials, we developed "Precursor of apatite" (PrA) treatment on the PEEK surface to confer bone-bonding properties. The advantages of this treatment are that it does not require high-temperature processing or special chemicals, and it is inexpensive. The present study clarified excellent in vivo bone-bonding property of PrA treatment. In addition, the results revealed important insights indicating that optimal conditions, especially wettability and crystallinity in calcium phosphate, differ at cell and organism levels. Moreover, our results indicated that prediction of in vivo bioactivity should be done in combination with multiple in vitro tests. (C) 2019 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.